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ORIGINAL ARTICLE
Decreased Ocular Pulse Amplitude and Retinal Nerve
Fibre Layer in Multiple Sclerosis
Ebru N. Cetin1, Cagdas Erdogan2, Semra Acer1, Gülden Sarac1, Cem Y|ld|r|m1,
and Levent S. Bir2
1Departments of Ophthalmology and 2Neurology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
ABSTRACT
This study was conducted to assess ocular pulse amplitude and retinal nerve fibre layer in patients with
multiple sclerosis and their correlation with disease duration and with severity. Retinal nerve fibre layer
thickness was measured by Heidelberg Retinal Tomography II (HRT-II; Heidelberg Engineering, Dossenheim,
Germany) and ocular pulse amplitude was measured by dynamic contour tonometry (Ziemer Ophthalmic
Systems, Port, Switzerland) in 37 multiple sclerosis patients and 72 age- and gender-matched controls. Ocular
pulse amplitude was significantly reduced and retinal nerve fibre layer was significantly thinner in temporal,
superotemporal, and nasal sectors in patients with multiple sclerosis regardless of having an optic neuritis
attack. The retinal nerve fibre layer was thinner in eyes with a previous optic neuritis attack compared with the
eyes without an attack, but the difference was not significant. Ocular pulse amplitude showed a positive
correlation with visual evoked potential amplitude and a negative correlation with visual evoked potential
latency. Retinal nerve fibre layer thickness showed a significant negative correlation with the disease duration
but not with visually evoked potential, disease severity, nor previous optic neuritis. These findings indicate that
the process of degeneration starts in the early period of the disease, as our study group is composed of early–
middle-stage multiple sclerosis patients, and is independent of relapses.
Keywords: Multiple sclerosis, ocular pulse amplitude, optic neuritis, retinal nerve fibre layer, visual evoked
potential
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory
and neurodegenerative disease characterized
by axonal injury in the central nervous system.1
Among various ophthalmic abnormalities, optic
neuritis is the most widely described visual disturb-
ance in MS, but less common manifestations
such as uveitis and ophthalmoplegia secondary
to cranial nerve palsy may also occur.2,3 Recently,
it was reported that retinal nerve fibre layer
(RNFL), which comprises non-myelinated axons of
retinal ganglion cells, reflects the disease activity
in MS.1,4
The underlying pathophysiology is unknown, but
some recent models support the presence of three
mechanisms including inflammation, demyelination,
and neurodegeneration in MS.4 A secondary vascular
dysfunction has also been proposed, which might
cause a reduction in optic disc and choroidal
perfusion.5
Ocular pulse amplitude (OPA) is the difference
between the systolic and diastolic intraocular pressure
(IOP).6–8 OPA is accepted as an indirect indicator of
choroidal perfusion that reflects the ocular blood flow
corresponding to the heart pulse.7 OPA can be
measured by dynamic contour tonometry, which is a
slit lamp mounted contact tonometer that uses a
transcorneal method to measure IOP. The tonometry
gathers 100 IOP readings per second, records dynamic
IOP, and therefore measures not only IOP but also
the OPA.
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Since its introduction as an indicator of choroidal
blood flow, OPA has been investigated and evaluated
in different clinical settings such as glaucoma, Behçet
disease, thyroid ophthalmopathy, and carotid artery
stenosis.9–12 In MS, a reduction of ocular blood flow in
retro-orbital vessels had been shown by Doppler
ultrasonography (USG); however, until now OPA in
MS patients has not been reported.13–15 In this study,
we aimed to measure OPA and to determine any
changes in choroidal perfusion in patients with MS.
Another objective of this study was to evaluate RNFL
changes in MS patients and to find out whether a past
history of optic neuritis (ON) attack affects OPA and
RNFL.
METHODS
Patients with a diagnosis of MS were included in this
prospective study after institutional board approval.
The control group consisted of healthy subjects who
were recruited from the hospital staff. All participants
provided informed consent to participate in the study.
Both eyes from each participant were included in
the study. Exclusion criteria were a history of
intraocular surgery; ON episode within 2 months
prior to the beginning of the study; coexistent ocular
disease (glaucoma, uveitis, etc.); significant refractive
error (more than 4 dioptres of spherical equivalent
refraction or 3 dioptres of astigmatism); any vascular
or autoimmune diseases (diabetes mellitus, hyperten-
sion, Buerger, vasculitis etc.); or any media opacity
that could prevent optimum imaging by retinal
tomography.
The study group consisted of patients who were
diagnosed as definite relapsing remitting MS accord-
ing to modified McDonald criteria.16 All patients were
relatively in the early–middle phases of the disease.
All patients had two or more attacks and those with
the diagnosis of clinical isolated syndrome were
excluded from the study. The time elapsed from the
last attack was at least 1 month for all patients
included in the study. The duration of MS was
4.97 3.47 (1–15) years and the mean time period
since last attack was 11.2 5.1 months (Table 1).
Disease duration, the Expanded Disability Status
Scale (EDSS), and treatments were documented by
the neurologist. EDSS was designed for defining the
neurological disability of patients with MS and
ranged from 0 to 10 (0 reveals normal neurological
examination while 10 means death). The diagnosis of
ON was based on clinical findings, which included
the presence of decreased visual acuity and colour
vision, visual field defect, relative afferent pupil
defect, and a compatible fundus examination.
Each eye was considered separately in the study.
Participants had detailed ophthalmic evaluation
including best-corrected visual acuity and intraocular
pressure measurement, biomicroscopic anterior seg-
ment, and dilated posterior segment examination.
Additionally, OPA, visually evoked potential (VEP),
and RNFL analyses were performed in all
participants.
Ocular pulse amplitude was measured by dynamic
contour tonometry (Ziemer Ophthalmic Systems,
Port, Switzerland). Topical proparacaine 0.5% was
applied before each measurement. OPA measurement
was performed according to the methods that had
been described previously and the measurements of
acceptable quality (Q1 to Q3) were recorded.7,17
RNFL thickness measurements were performed by
Heidelberg Retinal Tomograph II (HRT-II; Heidelberg
Engineering, Dossenheim, Germany). HRT is a con-
focal laser scanning system that creates a three-
dimensional (3D) image of the optic nerve and gives
information about optic nerve and peripapillary
RNFL. Stereometric parameters were calculated auto-
matically by the software. The values obtained from
the HRT-II scan for the study included RNFL thick-
ness in temporal, superotemporal, inferotemporal,
nasal, superonasal, and inferonasal sectors.
Visually evoked potentials (VEPs) were examined
in a quiet room with dimmed light (30 lux). For VEP
recordings subjects were seated 1 m away from a
television monitor. Tests were performed by a
computerized electromyography (EMG) device
(Medelec Premiere Plus, Vickers Medical - Medelec
Ltd, Woking, UK). Stimuli were given as a checker-
board pattern of black and white squares while
subjects were instructed to look to a point in the
middle of the screen with one eye closed. Needle
electrodes were inserted into the scalp in the midline
TABLE 1 Clinical characteristics of patients with multiple
sclerosis (MS).
MS duration (years)
Mean SD 4.97 3.47
Range 1–15
EDSS
Mean SD 1.37 1.08
Range 0–4.5
Time period since last MS attack (months)
Mean SD 11.2 5.1
Treatment n (%)
Interferon 23 (62.1)
Glatiramer 11 (29.7)
None 3 (8.1)
Number of eyes with ON attack n (%) 19 (27.5)
VEP amplitude (mv)
Mean SD 10.1 15.5
Range 2.6–135
VEP latency (ms)
Mean SD 118.5 18.4
Range 13–153
N = 37 for MS patients.
EDSS = Expanded Disability Status Scale; ON = optic neuritis;
VEP = visual evoked potentials.
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over the occipital region 2.5 cm above the inion (Oz:
active electrode) and over the frontal region (Fz:
reference). The ground electrode was placed on the
forearm. During the test 256 responses were averaged
for both eyes and were analysed in terms of peak
latencies and peak-to-peak amplitudes of the maximal
negative and positive deflections determined by
visual inspection: the N75 peak was defined as the
most negative point, P100 as the most positive point
following N75, and N145 as the second most negative
point. P100 latency and amplitudes were recorded for
each subject.
Statistical analysis was performed by SPSS statis-
tical software (SPSS 17.0.0 for MS Windows; SPSS,
Chicago, IL, USA). Descriptive statistics were
expressed as mean SD. Student’s t test was used to
compare means of the study and the control groups
for each variable.
RESULTS
A total of 37 MS patients (69 eyes) and 42 controls (84
eyes) were included in the study. The mean age was
38.78 11.22 years in MS group and 35.97 6.82 years
in the control group. There were 32 females (86.5%)
and 5 males (13.5%) in MS group, whereas there were
28 females (66.7%) and 14 males (33.3%) in the control
group. The groups were not significantly different in
terms of age and gender (p = 0.192 and p = 0.064,
respectively). In MS group, 19 eyes (27.5%) had
previous ON attack. Table 1 shows the clinical
characteristics of patients with MS.
Ocular Pulse Amplitude
OPA was significantly lower in MS group (2.16 0.93)
than the control group (2.57 1.08; p = 0.014). When
MS group was divided into two groups based on
having an ON attack or not, OPA did not significantly
differ between the groups (2.12 0.81 in eyes with an
ON attack versus 2.18 0.97 in eyes without an ON
attack; p = 0.820). OPA showed a significant positive
correlation with VEP amplitude and a negative
correlation with VEP latency but not with disease
duration and severity (Table 2).
Retinal Nerve Fibre Layer
RNFL was significantly thinner in temporal, super-
otemporal and nasal sectors in MS group compared
with the control group (p = 0.017, p = 0.049, and
p = 0.039, respectively; Table 3). In MS group, RNFL
thickness was not significantly different in any of the
sectors based on having a previous ON attack or not.
In MS group, RNFL thickness in temporal sector
significantly and negatively correlated with the dis-
ease duration (r =0.244, p = 0.043) but not with
disease severity, VEP amplitude, and latency (Table 4).
DISCUSSION
The novel finding in our study was that OPA, an
indirect indicator of choroidal perfusion, was signifi-
cantly reduced in patients with MS, regardless of a
past history of ON, when compared with healthy
controls. RNFL was significantly thinner in temporal,
superotemporal, and nasal sectors in patients with MS
compared with controls. RNFL was thinner in eyes
with previous ON attack compared with the eyes
without an attack, but the difference was not statis-
tically significant.
TABLE 3 The comparison of retinal nerve fibre layer (RNFL) thickness in patients with multiple sclerosis (MS) and the control group.
MS group
ON attack (þ)
(n = 19)
ON attack ()
(n = 50) p Value
Total MS
(n = 69)
Control group
(n = 84) p Value
Mean RNFL (mm) 0.24 0.05 0.26 0.06 0.231 0.25 0.05 0.27 0.06 0.120
Temporal RNFL (mm) 0.08 0.02 0.09 0.02 0.340 0.08 0.02 0.09 0.02 0.017
Superotemporal RNFL (mm) 0.28 0.08 0.30 0.06 0.210 0.29 0.07 0.32 0.07 0.049
Inferotemporal RNFL (mm) 0.25 0.08 0.29 0.08 0.101 0.28 0.08 0.29 0.08 0.639
Nasal RNFL 0.28 0.08 0.29 0.07 0.414 0.29 0.08 0.32 0.1 0.039
Superonasal RNFL (mm) 0.35 0.08 0.35 0.09 0.891 0.35 0.08 0.36 0.09 0.517
Inferonasal RNFL (mm) 0.34 0.08 0.37 0.11 0.314 0.36 0.1 0.38 0.09 0.220
The table also shows the comparison of RNFL thickness in MS patients with or without previous optic neuritis (ON) attack.
p values significant at50.05 are shown in bold.
TABLE 2 The correlation between ocular pulse
amplitude (OPA) and the disease duration, disease
severity (EDSS), and visual evoked potential (VEP)
amplitude and latency in patients with multiple sclerosis.
n r p
Duration 69 0.118 0.332
EDSS 69 0.039 0.749
VEP amplitude 66 0.269 0.029
VEP latency 66 0.294 0.017
r = correlation coefficient.
p values significant at50.05 are shown in bold.
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A reduction in ocular blood flow was shown by
Doppler USG in patients with MS. Hradilek et al.15
noticed a short-term effect in ocular blood flow
following ON attack, which was lost in the chronic
phase. Modrzejewska et al.14 showed decreased blood
flow parameters both in eyes with previous ON attack
and in fellow, unaffected eyes of MS patients.
Similarly, Pache et al.13 reported significantly reduced
blood flow velocity in ocular vessels in MS patients
regardless of a previous ON attack, indicating a
general reduction of retrobulbar blood flow in these
patients. In our study, OPA was significantly reduced
in patients with MS regardless of having an ON attack
compared with healthy controls. The suggested mech-
anism for this reduction of perfusion is vasoconstric-
tion secondary to increased levels of serum
endothelin-1 (ET-1), which is a potent vasocon-
strictor.5,13 Matrix metalloprotease-2, which is
expressed in and around MS plaques, is identical to
the endothelin-converting enzyme, which changes the
precursor protein big endothelin-1 to its active form
ET-1 and might be responsible from the increased
levels of ET-1 in MS patients.13,18,19 It was proposed
that high ET-1 level affects choroidal and optic nerve
head circulation and causes a reduction in the blood
flow of retroocular vessels and a slight paleness in the
optic nerve head.5 More evidence is needed to claim
that there is an association between OPA and ET-1
levels, and it is unclear whether ocular hypoperfusion
is a secondary pathology in addition to demyelination
and degeneration process in MS.
Recent studies have revealed that RNFL was
significantly affected in MS and this reduction of
RNFL thickness was not limited to eyes with a
previous ON attack. Oberwahrenbrock et al.20
reported that eyes of MS patients without a previous
ON showed a significant reduction of RNFL thickness
compared with healthy controls. Fernandes et al.21
showed that RNFL thickness was significantly
reduced in patients with MS, either with or without
ON. Similarly, in our study, RNFL was significantly
thinner in MS patients than controls and in MS group,
the difference in RNFL between eyes with or without
ON was not significant. Although RNFL thinning
occurred in eyes of patients with MS in general, some
investigators found that the thinning could be greater
in eyes with ON attack.4,22 However, having ON
attack was not associated with further progressive
thinning compared with fellow eyes and was not a
risk factor for increased chronic damage in MS
patients without ophthalmic relapses.4 This loss of
RNFL was believed to reflect the progressive degen-
eration associated with the disease and it was more
prominent in more advanced stages of the disease.4,22
However, we found significant thinning in an early–
middle stage MS group. This finding indicates that
degeneration starts earlier, long before the disease
becomes advanced. Briefly, the measurement of RNFL
appears to be a valuable tool for monitoring the
progression of axonal degeneration in MS disease.1
MS primarily affects young women, which can
explain the relative predominance of female patients
in our study.23 This predominance may bring the
question of possible effect of gender on our findings.
However, our study and control groups were well
balanced in terms of gender. Additionally, the previ-
ous studies did not reveal an association between
gender and RNFL.24 Therefore, we believe that our
findings were not significantly affected by the
predominancy of females in our study group.
Our findings revealed that OPA and RNFL thick-
ness were significantly reduced in MS patients
regardless of having an ON attack. OPA significantly
correlated with VEP amplitude, which reflects the
axonal damage, and VEP latency, which reflects the
demyelination. However, the lack of correlation
between RNFL, VEP, disease severity, and ON attacks
suggests that this degeneration process is independ-
ent from attacks. The newly emerging concept is that
the course of MS disease is defined by the appearance
of neurological symptoms during attacks and by
ongoing progressive subclinical axonal degener-
ation.25 Our findings also indicate that degeneration
starts in the early period of the disease, since our
study group is composed of early–middle-stage MS
patients. However, since this topic remains
TABLE 4 The correlation between retinal nerve fibre layer (RNFL) thickness and the disease duration, disease severity (EDSS), and
visual evoked potential (VEP) amplitude and latency in patients with multiple sclerosis (MS).
MS Duration (n = 69) EDSS (n = 69) VEP amplitude (n = 66) VEP latency (n = 66)
r p r p r p r p
Mean RNFL 0.114 0.351 0.060 0.627 0.039 0.754 0.030 0.814
Temporal RNFL 0.244 0.043 0.043 0.725 0.129 0.304 0.061 0.626
Superotemporal RNFL 0.137 0.266 0.050 0.687 0.147 0.243 0.022 0.861
Inferotemporal RNFL 0.173 0.155 0.127 0.298 0.011 0.931 0.047 0.706
Nasal RNFL 0.020 0.873 0.055 0.653 0.067 0.591 0.076 0.546
Superonasal RNFL 0.045 0.716 0.026 0.830 0.158 0.204 0.107 0.391
Inferonasal RNFL 0.046 0.707 0.125 0.307 0.077 0.538 0.007 0.954
r = correlation coefficient.
p values significant at50.05 are shown in bold.
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controversial in the scientific literature, further studies
with larger sample sizes are needed.
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Inflamm 2011;19:376–378.
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